Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Kineret Arthritis Product Being Watched By Medco For Cost Impact

Executive Summary

Merck-Medco anticipates FDA approval for Amgen's rheumatoid arthritis treatment Kineret as early as the first quarter of 2001. The PBM is keeping close track of development of the drug as one of a handful of R&D projects that could have a significant impact on drug spending when they reach the market.

You may also be interested in...



Rx Cost Management Should Emphasize Generics Over Rebates - BC/BS Exec

The goal for pharmacy managers should be a decline in drug budgets over the next few years in light of patent expirations, Regence Blue Shield of Idaho Assistant VP-Pharmacy Services Terrance Killilea told the Pharmaceutical Benefit Management Institute April 28 in Scottsdale, Ariz.

Rx Cost Management Should Emphasize Generics Over Rebates - BC/BS Exec

The goal for pharmacy managers should be a decline in drug budgets over the next few years in light of patent expirations, Regence Blue Shield of Idaho Assistant VP-Pharmacy Services Terrance Killilea told the Pharmaceutical Benefit Management Institute April 28 in Scottsdale, Ariz.

Bristol Vanlev Launch Resources Will Shift To Pravachol; NDA Withdrawn

Bristol plans to reallocate some of the money reserved for the launch of the antihypertensive Vanlev to help revive the cholesterol-lowering agent Pravachol.

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel